• Oral anticancer medications have become more widely available for the treatment of a broad number of cancers and have increasingly been used as an alternative to intravenous therapy.
• In order to be equally effective as intravenous therapies, such oral treatments require that patients sufficiently adhere to prescription guidelines.
• Adherence to anticancer medication regimens has been found to be difficult to predict and to vary widely between 16% and 100%.
What is already known about this subject
• This study evaluated utilization and adherence patterns for abiraterone acetate-which is a prodrug for abiraterone, a novel androgen biosynthesis inhibitor-and for concomitant prednisone use in patients with prostate cancer in the United States.
• It was found that the vast majority of patients took abiraterone acetate plus prednisone in a manner that is consistent with the prescribing information over the period of time they had evidence of use (discontinuation was not evaluated). The mean daily dose was within 1% of the recommended dose, and adherence was high with a mean medical possession ratio above 90%.
• Similar adherence patterns were observed for patients in different age groups and for patients with commercial health care plans versus patients with Medicare coverage. • These findings support providers' understanding of the consistency with which AA-treated prostate cancer patients take their medication.
or Medicare supplemental coverage through privately insured fee-for-service, point-of-service, or capitated health plans. All census regions are represented, although most enrollees are from the South and North Central regions. The Symphony Health Solutions' ProMetis Lx database (Dataset 2) is an integrated database that consists of health care billing transactions between payers, hospitals, pharmacies, and physicians. The dataset consists of over 12 billion claims representing over 200 million unique patients between 2010 and 2012. Approximately 9,000 different payers are represented in the data source (health plans, and government and public organizations). All census regions are represented.
Data elements in both databases include medical claims for outpatient and inpatient services, pharmacy claims for prescription drugs, and information on demographics and health plan characteristics. The datasets collect information from different sources of the health care claim life cycle. Dataset 1 is based on adjudicated insurance claims and therefore captures all insurance-paid services provided to its members for the duration of their enrollment in the dataset. Dataset 1 captures claims only for members participating in the employer health plans unique to the dataset. It does not capture claims that may have been paid by cash or by secondary commercial insurance sources, except for Medicare enrollees.
Dataset 2 captures health care claims transactions through participating claims-processing intermediaries independently of a patient's participation in a health plan or payer type. Prescriptions or health care services that were processed through third-party claims transaction networks that do not participate in the dataset are not present. In the case of drugs, such as AA, which have limited distribution through specialty pharmacy providers, the claims-processing intermediaries used by an individual specialty pharmacy are unlikely to change, supporting an assumption of complete claims history for drugs from specialty providers. In order to increase the likelihood that patients were present in the dataset during the full study period, the transaction history of the patient's clinical activity was monitored by calendar quarters (3-month intervals) where patients have at least 1 prescription, diagnosis, or procedure claim recorded in the database. This method of monitoring clinical activity transactions was used to define the continuous observation period.
In both datasets, patient-level data were de-identified in compliance with the Health Insurance Portability and Accountability Act of 1996 to preserve patient confidentiality. Institutional review board approval and informed consent were not required for this study.
The databases were chosen for their complementary strengths in data coverage and sample size. Dataset 1 (Truven) has the ability to follow patients longitudinally with confidence that complete claims are available since eligibility for services, but this dataset covers a smaller number of eligible patients. This availability of oral anticancer agents aligns with the preferences of cancer patients and may help to improve patients' quality of life and reduce time spent in health care settings, goals that are particularly important in palliative care. 8 However, oral anticancer treatments also pose the challenge of ensuring that patients adhere to prescription guidelines. Without sufficiently ensuring adherence, treatment with oral agents may be less effective than their intravenous alternatives. For instance, suboptimal adherence to targeted oral anticancer medications has been shown to deteriorate event-free survival in patients with chronic myelogenous leukemia. 9 Breast cancer patients who filled fewer than 70% of their tamoxifen prescriptions have been found to have an increased risk of death. 10 Consequently, with the growing use of oral agents, the problem of nonadherence has received increasing attention in oncologic care and research. Several studies evaluating adherence to anticancer medication regimens found that adherence is difficult to predict and varies widely between 16% and 100%. 5, 6 Few studies have investigated real-world adherence patterns for an oral antineoplastic agent and concomitant prednisone use in patients with prostate cancer in the United States. This this may be partly due to the relatively recent U.S. Food and Drug Administration (FDA) approvals of such oral agents as abiraterone acetate (AA) or enzalutamide for this patient population. AA, a prodrug of abiraterone that is a novel androgen biosynthesis inhibitor, was approved in 2011 to be used in combination with prednisone as treatment for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. In 2012, the approval was extended to chemotherapy-naïve patients. According to the prescribing information, AA is administered orally in a daily dose of 1,000 milligrams (mg) combined with 10 mg of oral prednisone.
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This study evaluated utilization and adherence for AA and concomitant prednisone use in commercially or Medicarecovered patients with prostate cancer in the United States, using health insurance claims from 2 large U.S. administrative health care claims databases. The Truven database (Dataset 1) is a large, closed administrative claims dataset containing health care claims for employees, retirees, and their dependents covered by more than 100 payers (health plans and government and public organizations). It consists of approximately 500 million claims representing approximately 50 million covered lives during the study time period. Health care coverage types include primary Dataset 2 (Symphony) provides the benefit of a relatively large and more current sample, which is important given the short time since AA approval.
Study Design and Patient Selection Criteria
Both datasets were used to conduct retrospective cohort studies of patients with at least 1 AA claim, as outlined in Figures 1A and 1B. Patients were newly initiated on AA, and the date of the first claim served as the index date.
In Dataset 1, patients were required to be continuously enrolled for medical and pharmacy benefits during the 6 months before and after the index date in order to be included in the primary study population. Using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), patients also had to have at least 1 prostate cancer diagnosis (ICD-9-CM 185.xx) and at least 1 metastatic diagnosis (ICD-9-CM 196.xx to 199.xx) 6 months prior to the index date, as well as at least 1 prostate cancer diagnosis after the index date. All patients had an observation period of 6 months following the index date. A subset of patients with 9 and 12 months of continuous eligibility were also evaluated.
In Dataset 2, patients were required to have at least 2 quarters of clinical activity prior to the index period and continuous quarters of clinical activity post-index in order to be included in the study population. Clinical activity was defined by the presence of at least 1 transaction in the database. Patients also had to have at least 1 prostate cancer diagnosis (ICD-9-CM 185.xx, V10.46) during the pre-index baseline period. Because this dataset may not record all medical diagnoses received by patients, a metastatic diagnosis during the baseline period was not imposed. The post-index observation period for Dataset 2 spanned from the index date until the end of clinical activity. The follow-up time hence varied across patients.
Outcomes and Statistical Analyses
In order to evaluate treatment and adherence patterns for AA, the daily dose was evaluated for all patients, and the medication possession ratio (MPR) was assessed for patients with at least 2 AA claims. The daily dose per day per prescription was calculated as the quantity dispensed divided by the days of supply and multiplied by 250 mg. The mean dose per day per prescription was calculated for each patient, and the mean across patients is reported. The MPR is a measure of consistency and was obtained by dividing the sum of days of supply of AA by the total number of days on therapy. The days on therapy were defined as the days between the day of the first AA claim and the last day of supply of the last AA refill. Note that this definition focuses on the medication refill patterns over the period of time when AA was theoretically available.
To complement this adherence information, the percentage of patients treated with AA who concomitantly received prednisone was reported together with mean daily prednisone dose for patients with at least 1 AA claim. Measurement of persistency was not a focus of this analysis for a variety of reasons, including the recency of AA availability in the United States, differences in the amount of follow-up time available in the various databases, and the unavailability of reasons for medication discontinuation and verification of medication discontinuation in the datasets. Furthermore, in patients with progressive cancer, medication persistence or the length of time a patient remains on therapy may be a less meaningful measure than consistent patterns of adherence to medication taking, since medication discontinuation may occur for a variety of reasons that are not apparent within the dataset and are not under the patient's control, such as the stage of disease at treatment initiation, disease progression, or other medical complications. Evaluation of persistency in the absence of these additional parameters diminishes the value of persistency metrics in advanced cancer conditions. In order to evaluate adherence patterns for patients with varying baseline characteristics, the study population from both datasets was stratified into 4 age groups, 2 health care plan types (Medicare and commercial health care coverage), and into patients with and without recent chemotherapy treatment. In Dataset 1, recent chemotherapy treatment was defined as chemotherapy within 180 days before initiation of AA. In Dataset 2, a patient was included in the recent chemotherapy cohort if any chemotherapy was administered in the period between start of clinical activity and index date.
Univariate descriptive statistics included mean (± standard deviation [SD]) and median values for continuous variables and relative frequencies for categorical variables. All analyses were conducted using SAS Version 9.3 for Windows (SAS Institute, Cary, NC). Table 1 shows the baseline characteristics for both datasets. Figure 2 illustrates the sample selection flowchart. A total of 515 patients (mean ± SD age: 72.2 ± 9.7 years) with at least 1 AA claim were selected from Dataset 1 into Study Population 1, while 3,228 patients (mean ± SD age: 72.2 ± 8.0 years) were selected into Study Population 2. A subpopulation of 492 patients in Dataset 1 and 2,449 patients in Dataset 2 had at least 2 AA prescription claims. In Dataset 1, 26% of patients were covered by a commercial health care plan, and 74% were covered by Medicare. In Dataset 2, coverage was slightly more balanced with 55% and 40.4%, respectively. In Dataset 1, 50.1% of patients had recently been treated with chemotherapy; in Dataset 2, 30.5% of patients had recently been treated with chemotherapy. Table 2 provides AA utilization and adherence patterns for both datasets. The mean (median) daily AA dose per patient per prescription was 998.8 (1,000) mg for Dataset 1 and 994.2 (1,000) mg for Dataset 2, which corresponds to the recommendation of the prescribing information of 1,000 mg daily. Mean (median) MPR was 93% (98%) in Study Population 1 and 93% (100%) in Study Population 2. AA utilization, prednisone utilization, and MPR were similar in Study Population 1 when observation periods of at least 9 and 12 months were evaluated. Table 2 shows that in Dataset 1, 95% of patients treated with AA also used prednisone during the 6-month observation period. The results from Dataset 2 show that 75.1% of patients used prednisone concomitantly to being treated with AA. The mean (median) daily prednisone dose per patient per prescription is similar in both datasets with 10.1 (10.0) mg and 10.6 (10.0) mg in datasets 1 and 2, respectively. This dose is consistent with the recommendation of 10 mg per day. Patients that were concomitantly treated with prednisone had AA adherence patterns that were similar to those of patients that did not have a claim for prednisone while being treated with AA.
■■ Results

Adherence Patterns
Concomitant Prednisone Use
Baseline Characteristics and Adherence
In both datasets, similar adherence patterns, captured by the MPR, were observed for patients in different age groups, for 
TABLE 2
Abiraterone Acetate Utilization and Adherence Patterns izing hormone-releasing analogs) in patients with localized high-risk prostate cancer in Canada. 12 They found that 93% of patients adhered strictly to 1 month of bicalutamide treatment. The transferability of the results to real-world adherence patterns is nevertheless limited, since 1 month is a relatively short observation period. In addition, adherence rates observed in clinical trials may overestimate real-world adherence, since trial participants tend to be carefully selected and/or comparatively more motivated than the general patient population. 13 Close monitoring may further encourage patients to adhere to the prescribed treatment regimen. 13 Analyzing health care claim records may thus be a better approach for exploring real-world adherence patterns to cancer treatments. While this type of analysis has been increasingly used, most recent studies have focused on breast cancer, with only a few focusing on prostate cancer. 5, [14] [15] [16] Using health care claims, Grundmark et al. (2012) investigated anti-androgen patient treatment adherence and influencing factors, primarily for bicalutamide, in men with incident prostate cancer. 17 The authors found that 60% of men had adherence rates of over 80%, as measured by the flexible MPR (ratio of the number of days of prescribed supplies dispensed to the number of days in the study period). Since the analysis is based on nationwide data from Sweden, its results may not be completely transferable to the United States. Keisner et al. (2010) analyzed U.S. data in a retrospective analysis and found adherence rates for ketoconazole treatment of 82% to 100%, but the small size of their study population (30 patients) substantially limits the generalizability of the results. 18 Using a larger sample from the Veteran's Health Administration dataset, Bui et al. (2013) studied timing and adherence to life-extending therapy (LET; cabazitaxel, docetaxel, AA) and corticosteroids in patients with metastatic castration-resistant prostate cancer. 19 They defined adherence as the total overlapping days of corticosteroids and LET prescriptions divided by total of LET prescription days patients with commercial health care plans versus patients with Medicare coverage, and for patients with recent chemotherapy compared with patients without chemotherapy (Table 3) .
Since most patients in the overall study population had at least 1 metastatic diagnosis prior to the index date (80%), a sensitivity analysis conducted on the subsample of patients with metastases yielded AA and prednisone utilization patterns that were very similar to the overall study population.
■■ Discussion
This study evaluated utilization and adherence patterns for AA and concomitant prednisone in commercially or Medicarecovered patients with prostate cancer in the United States using 2 large administrative health care claims databases. Results from both datasets showed that real-world daily AA and prednisone doses are consistent with prescribing information, with a mean (median) daily AA dose of 998.8 (1,000) mg in Dataset 1 and 994.2 (1,000) mg in Dataset 2 and a mean (median) daily prednisone dose of 10.1 (10.0) mg and 10.6 (10.0) mg, respectively. Adherence to AA between the starting and ending dates where AA was available was high among patients from both datasets, with a mean MPR above 90%. These findings support providers' understanding of the consistency with which AA-treated prostate cancer patients take their medication. To the knowledge of the authors, the study presented here is among the first to use large health care claims databases to investigate real-world adherence patterns for an oral antineoplastic agent and concomitant prednisone use in patients with prostate cancer in the United States.
Previous studies on adherence to cancer treatment have evaluated clinical trials, investigated other types of cancer (primarily breast cancer), and/or focused on other countries. Nabid et al. (2012) 
Conclusions
This retrospective study found that during the 6-month observation period, the vast majority of AA-treated prostate cancer patients take AA plus prednisone in a manner that is consistent with the prescription information, with a mean MPR above 90% (median = 100%) in samples drawn from 2 different large U.S. databases. Similar adherence patterns were observed over longer observation periods as well as for patients in different age groups and for patients with commercial health care plans versus patients with Medicare coverage. The findings of this study can provide useful insights into the real-world adherence patterns for AA-treated prostate cancer patients and can contribute to the current discussion in oncologic research and practice. and found that it was over 80%. However, this provides little information about adherence to AA specifically.
The study presented here used 2 large administrative health care claims databases in order to provide comprehensive insight into treatment and adherence patterns for AA. Although the 2 databases utilize different methods of data capture, among other characteristic differences discussed in the methodology section, AA adherence was remarkably similar in both data source populations, supporting the validity of the results.
This study also investigated adherence among different subgroups based on certain baseline characteristics. It found similar adherence patterns for patients in different age groups, for patients with commercial health care plans versus patients with Medicare coverage, and for patients with recent chemotherapy compared with patients without chemotherapy. Our findings with respect to age and health care plan are consistent with the literature. While Grundmark et al. 17 found that older men had a lower adherence rate, the overall literature has not revealed age to be a consistent predictor of compliance with cancer treatments.
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Limitations
As with all analyses, some limitations must be taken into consideration. This study used data from 2 different administrative health care claims databases. Analyses based on claims data have inherent limitations, such as potential miscoding or incomplete coding of diagnoses. Pharmacy claims for dispensing events may not reflect patients' actual compliance to the medications. Due to the limitations in ICD-9-CM coding specificity, staging information or verification of castrationresistant prostate cancer was not possible. There is potential for the 2 datasets to overlap, but the actual overlap cannot be determined, since the databases are not linked. In addition, the 2 databases used are not completely comparable: Dataset 1 is insurance-based and Dataset 2 is provider-based. Instead of combining the datasets, the analysis was conducted on both datasets separately. For Dataset 1, the small sample size may limit the generalizability of the findings, particularly within subgroups. Dataset 2 may not contain records on some prescriptions or health care services that were processed through different claims transaction networks. Due to this particularity and the approximation of eligibility by clinical activity, utilization may be underestimated in Study Population 2. Moreover, an apparent treatment interruption observed in the data may in fact be a patient receiving his health care service outside of the networks captured in the database. However, the consistency of results across these 2 distinct databases adds to the validity and robustness of the results. Finally, the study presented here was limited to evaluating utilization and adherence patterns for AA and concomitant prednisone use by men with prostate cancer in the United States. Other findings may be reported for other global geographic regions.
